Skip to main content

Cachexia

17
Pipeline Programs
16
Companies
11
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
12
0
2
0
3
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

14 companies ranked by most advanced pipeline stage

Helsinn
HelsinnIreland - Dublin
3 programs
3
Anamorelin HClPhase 31 trial
Anamorelin HClPhase 31 trial
Anamorelin HClPhase 31 trial
Active Trials
NCT01387269Completed484Est. Feb 2015
NCT01387282Completed495Est. Feb 2015
NCT01395914Completed513Est. Feb 2015
ViiV Healthcare
ViiV HealthcareNC - Durham
5 programs
4
1
GSK2881078Phase 2
Deuterated WaterPhase 1
GSK2849466Phase 1
GSK2881078Phase 1
GSK2881078Phase 1
Sandoz
SandozAustria - Kundl
2 programs
1
BYM338 active drugPhase 2
Muscle Wasting in Cancer (MWIC)N/A
Pfizer
PfizerNEW YORK, NY
2 programs
2
PF-05230901Phase 11 trial
PF-06946860Phase 11 trial
Active Trials
NCT01262690Terminated44Est. Sep 2011
NCT04299048Completed11Est. Mar 2022
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
1
DronabinolPhase 1
NGM Biopharmaceuticals
1 program
1
NGM120Phase 11 trial
Active Trials
NCT03392116Completed92Est. Mar 2019
Quotient Therapeutics
Quotient TherapeuticsMA - Cambridge
1 program
1
Part 1 Group 1 Regime APhase 11 trial
Active Trials
NCT06028321Completed51Est. Jun 2022
Actimed Therapeutics
Actimed TherapeuticsUK - Berkshire
1 program
1
Part 1 Group 1 Regime APhase 1
Endevica Bio
Endevica BioIL - Northbrook
1 program
1
TCMCB07Phase 11 trial
Active Trials
NCT05529849Completed76Est. Feb 2023
Biocorp
BiocorpFrance - Issoire
1 program
1
TCMCB07Phase 1
Novartis
NovartisBASEL, Switzerland
1 program
Muscle Wasting in Cancer (MWIC)N/A1 trial
Active Trials
NCT03191955Completed282Est. Aug 2025
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
The Investigation of the Mechanism of Cachexia Occurrence for Patients With Gastrointestinal CancerN/A1 trial
Active Trials
NCT04594863Unknown100Est. Jun 2021
Bristol Myers Squibb
1 program
DronabinolPHASE_11 trial
Active Trials
NCT00000737Completed56
Parexel
ParexelMA - Boston
1 program
GSK2881078PHASE_2

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
HelsinnAnamorelin HCl
HelsinnAnamorelin HCl
HelsinnAnamorelin HCl
Endevica BioTCMCB07
Quotient TherapeuticsPart 1 Group 1 Regime A
PfizerPF-06946860
NGM BiopharmaceuticalsNGM120
PfizerPF-05230901
UNION therapeuticsThe Investigation of the Mechanism of Cachexia Occurrence for Patients With Gastrointestinal Cancer
NovartisMuscle Wasting in Cancer (MWIC)

Clinical Trials (11)

Total enrollment: 2,204 patients across 11 trials

NCT01387269HelsinnAnamorelin HCl

Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1)

Start: Jul 2011Est. completion: Feb 2015484 patients
Phase 3Completed
NCT01387282HelsinnAnamorelin HCl

Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)

Start: Jul 2011Est. completion: Feb 2015495 patients
Phase 3Completed
NCT01395914HelsinnAnamorelin HCl

Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)

Start: Jul 2011Est. completion: Feb 2015513 patients
Phase 3Completed
NCT00000737Bristol Myers SquibbDronabinol

A Phase I/II Study to Evaluate Single Agent and Combination Therapy With Megestrol Acetate and Dronabinol for the Treatment of HIV-Wasting Syndrome

56 patients
Phase 1Completed
NCT05529849Endevica BioTCMCB07

A Study to Assess the Safety, Tolerability and Pharmacokinetics of TCMCB07 in Single and Multiple Ascending Doses in Health Subjects

Start: Jul 2022Est. completion: Feb 202376 patients
Phase 1Completed
NCT06028321Quotient TherapeuticsPart 1 Group 1 Regime A

Study of Comparative Bioavailability and Pharmacokinetics of ACM-001.1) and Pindolol in Healthy Volunteers (HV)

Start: Nov 2021Est. completion: Jun 202251 patients
Phase 1Completed
NCT04299048PfizerPF-06946860

Study to Assess the Safety and Tolerability of Repeated Doses of an Investigational New Drug in Patients With Cancer and Cachexia.

Start: Nov 2020Est. completion: Mar 202211 patients
Phase 1Completed
NCT03392116NGM BiopharmaceuticalsNGM120

Single and Multiple Ascending Dose Study of NGM120 in Healthy Adult Subjects

Start: Jan 2018Est. completion: Mar 201992 patients
Phase 1Completed
NCT01262690PfizerPF-05230901

A Study In Healthy Subjects Of Single Doses of PF-05230901 Injected Under The Skin

Start: Nov 2010Est. completion: Sep 201144 patients
Phase 1Terminated
NCT04594863UNION therapeuticsThe Investigation of the Mechanism of Cachexia Occurrence for Patients With Gastrointestinal Cancer

The Investigation of the Mechanism of Cachexia Occurrence for Patients With Gastrointestinal Cancer

Start: Nov 2020Est. completion: Jun 2021100 patients
N/AUnknown
NCT03191955NovartisMuscle Wasting in Cancer (MWIC)

Muscle Wasting in Cancer (MWIC)

Start: Nov 2015Est. completion: Aug 2025282 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs, potential near-term approvals
16 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.